Secondary Primary Cancer Prevention Strategies Following CAR T-Cell Therapy Are Underway
OncLive,
Saurabh Dahiya, MD, FACP Manufacturing and bioengineering strategies for CAR T products as well as the identification of…
CAR T-Cell Therapy Results in Secondary Primary Cancers in Approximately 4% of Patients
OncLive,
Shyam A. Patel, MD, PhD The rare development of second primary cancers (SPCs) following CAR T-cell therapy may be influenced by…
Evaluating the Risk of Second Primary Cancers After CAR T-Cell Therapy
Oncology Nursing News,
Assessment of the risks of SPCs associated with CAR T-cell therapies justifies further investigation into mitigation strategies.
Second Primary Cancer Risk Informs the Risk-Benefit Profile of CAR T-Cell Therapies
OncLive,
Hematology | Image credit: © Nittaya – stock.adobe.com Although the risk of developing second primary cancers (SPCs) following…